{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:46:33Z","timestamp":1791665193679,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220587\/Z\/20\/Z"],"award-info":[{"award-number":["220587\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The exposure and both\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    clearance rates and toxicity relationships of bedaquiline-pretomanid-linezolid- (BPaL), BPaL-clofazimine (BPaLC) and BPaL-moxifloxacin (BPaLM) for treatment of rifampicin-resistant tuberculosis remain understudied. Therefore, the relationship between the patients\u2019 exposure to anti-TB drugs in TB-PRACTECAL trial investigational regimens and their treatment outcomes was investigated. PRACTECAL-PKPD was a prospective pharmacokinetics and pharmacodynamics study. Patients with rifampicin-resistant tuberculosis were enrolled from Belarus and South Africa. Antimicrobial exposures for bedaquiline, pretomanid, linezolid, moxifloxacin and clofazimine were adequately estimated, were within the ranges of previously published studies but did not correlate with the speed of sputum bacterial clearance. When compared to the standard of care (SoC) arm, a 20% increased bacillary killing rate with BPaLM was observed, whilst BPaL and BPaLC displayed a 15% decreased rate. Also of note was a 20% decreased bacillary killing rate in patients with severe disease irrespective of treatment. Linezolid exposure was higher amongst patients with anaemia or neutropenia. No other exposure-toxicity relationships were identified for all other drugs. These data indicate that the studied doses of linezolid and moxifloxacin could be the right balance between effectiveness and safety, strengthening the WHO recommendation that BPaLM is the preferred regimen for rifampicin-resistant tuberculosis in adolescents and adults. The study was registered in Clinical Trials.gov, TRN: NCT04081077.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-74335-y","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:06:44Z","timestamp":1781075204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatment"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9915-5878","authenticated-orcid":false,"given":"Bern-Thomas","family":"Nyang\u2019wa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronelle","family":"Moodliar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varvara","family":"Solodovnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakira","family":"Rajaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6363-9387","authenticated-orcid":false,"given":"Catherine","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3748-0154","authenticated-orcid":false,"given":"David A. J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraint","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-4559","authenticated-orcid":false,"given":"Frank","family":"Kloprogge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"74335_CR1","unstructured":"Global tuberculosis report 2025. (Geneva: World Health Organization; 2025). Licence: CC BY-NC-SA 3.0 IGO."},{"key":"74335_CR2","unstructured":"WHO. WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment (World Health Organisation, 2022)."},{"key":"74335_CR3","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1128\/AAC.01418-13","volume":"58","author":"SC McLeay","year":"2014","unstructured":"McLeay, S. C., Vis, P., van Heeswijk, R. P. & Green, B. Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob. Agents Chemother. 58, 5315\u20135324 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"74335_CR4","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1126\/science.1164571","volume":"322","author":"R Singh","year":"2008","unstructured":"Singh, R. et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322, 1392\u20131395 (2008).","journal-title":"Science"},{"key":"74335_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2007.04.005","volume":"26","author":"KL Leach","year":"2007","unstructured":"Leach, K. L. et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell 26, 393\u2013402 (2007).","journal-title":"Mol. Cell"},{"key":"74335_CR6","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.4269\/ajtmh.1974.23.1097","volume":"23","author":"L Levy","year":"1974","unstructured":"Levy, L. Pharmacologic studies of clofazimine. Am. J. Trop. Med. Hyg. 23, 1097\u20131109 (1974).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"74335_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/jac\/44.3.393","volume":"44","author":"SH Gillespie","year":"1999","unstructured":"Gillespie, S. H. & Billington, O. Activity of moxifloxacin against mycobacteria. J. Antimicrob. Chemother. 44, 393\u2013395 (1999).","journal-title":"J. Antimicrob. Chemother."},{"key":"74335_CR8","doi-asserted-by":"crossref","unstructured":"Kwak, N. et al. Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysis. Eur. Respir. J. 66, 2500315 (2025).","DOI":"10.1183\/13993003.00315-2025"},{"key":"74335_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","volume":"12","author":"BT Nyang\u2019wa","year":"2024","unstructured":"Nyang\u2019wa, B. T. et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir. Med. 12, 117\u2013128 (2024).","journal-title":"Lancet Respir. Med."},{"key":"74335_CR10","doi-asserted-by":"crossref","unstructured":"Srivastava, S. et al. Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis. Antimicrob. Agents Chemother. 61, e00751-17 (2017).","DOI":"10.1128\/AAC.00751-17"},{"key":"74335_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1022090","volume":"14","author":"G Shao","year":"2023","unstructured":"Shao, G. et al. Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients. Front. Pharm. 14, 1022090 (2023).","journal-title":"Front. Pharm."},{"key":"74335_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1128\/AAC.01478-13","volume":"58","author":"SP Zvada","year":"2014","unstructured":"Zvada, S. P. et al. Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. Antimicrob. Agents Chemother. 58, 503\u2013510 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"74335_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1128\/AAC.00849-10","volume":"55","author":"Z Ahmad","year":"2011","unstructured":"Ahmad, Z. et al. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55, 239\u2013245 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"74335_CR14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie, F. et al. Treatment of highly drug-resistant pulmonary tuberculosis. N. Engl. J. Med. 382, 893\u2013902 (2020).","journal-title":"N. Engl. J. Med."},{"key":"74335_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa218","volume":"7","author":"F Kloprogge","year":"2020","unstructured":"Kloprogge, F. et al. Longitudinal pharmacokinetic-pharmacodynamic biomarkers correlate with treatment outcome in drug-sensitive pulmonary tuberculosis: a population pharmacokinetic-pharmacodynamic analysis. Open Forum Infect. Dis. 7, ofaa218 (2020).","journal-title":"Open Forum Infect. Dis."},{"key":"74335_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/civ195","volume":"61","author":"DJ Sloan","year":"2015","unstructured":"Sloan, D. J. et al. Pharmacodynamic modeling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis. Clin. Infect. Dis. 61, 1\u20138 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"74335_CR17","doi-asserted-by":"publisher","unstructured":"Nyang\u2019wa, B.-T. et al. Linezolid population pharmacokinetics in rifampicin-resistant tuberculosis patients and interpretation challenges of the probability of target attainment. Preprint at medRxiv https:\/\/doi.org\/10.64898\/2025.12.04.25340900 (2025).","DOI":"10.64898\/2025.12.04.25340900"},{"key":"74335_CR18","doi-asserted-by":"crossref","unstructured":"Nyang\u2019wa, B. T. et al. Population pharmacokinetics and target attainment of pretomanid in rifampicin-resistant tuberculosis patients. Sci. Rep. 16, 15255 (2026).","DOI":"10.1038\/s41598-026-46217-2"},{"key":"74335_CR19","doi-asserted-by":"publisher","unstructured":"Nyang\u2019wa, B.-T. et al. Clofazimine population pharmacokinetics and target attainment in rifampicin-resistant Tuberculosis patients. Preprint at medRxiv https:\/\/doi.org\/10.64898\/2025.12.04.25340990 (2025).","DOI":"10.64898\/2025.12.04.25340990"},{"key":"74335_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/psp4.12147","volume":"5","author":"EM Svensson","year":"2016","unstructured":"Svensson, E. M., Dosne, A. G. & Karlsson, M. O. Population pharmacokinetics of bedaquiline and metabolite M2 in patients with drug-resistant tuberculosis: the effect of time-varying weight and albumin. CPT Pharmacomet. Syst. Pharm. 5, 682\u2013691 (2016).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"74335_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00811-22","volume":"66","author":"J Zou","year":"2022","unstructured":"Zou, J. et al. Population pharmacokinetic modeling of bedaquiline among multidrug-resistant pulmonary tuberculosis patients from China. Antimicrob. Agents Chemother. 66, e0081122 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"74335_CR22","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.5588\/ijtld.21.0158","volume":"25","author":"H Zhu","year":"2021","unstructured":"Zhu, H. et al. Population pharmacokinetics of bedaquiline in patients with drug-resistant TB. Int. J. Tuberc. Lung Dis. 25, 1006\u20131012 (2021).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"74335_CR23","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","volume":"371","author":"SH Gillespie","year":"2014","unstructured":"Gillespie, S. H. et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577\u20131587 (2014).","journal-title":"N. Engl. J. Med."},{"key":"74335_CR24","doi-asserted-by":"crossref","unstructured":"Te Brake, L. H. M. et al. Increased bactericidal activity but dose-limiting intolerability at 50mg\u00b7kg(-1) rifampicin. Eur. Respir. J. 58, 2000955 (2021).","DOI":"10.1183\/13993003.00955-2020"},{"key":"74335_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1164\/rccm.2205007","volume":"166","author":"RJ O\u2019Brien","year":"2002","unstructured":"O\u2019Brien, R. J. Studies of the early bactericidal activity of new drugs for tuberculosis: a help or a hindrance to antituberculosis drug development?. Am. J. Respir. Crit. Care Med. 166, 3\u20134 (2002).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"74335_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06331-8","volume":"23","author":"C Berry","year":"2022","unstructured":"Berry, C. et al. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials 23, 484 (2022).","journal-title":"Trials"},{"key":"74335_CR27","doi-asserted-by":"publisher","first-page":"e047185","DOI":"10.1136\/bmjopen-2020-047185","volume":"11","author":"BT Nyang\u2019wa","year":"2021","unstructured":"Nyang\u2019wa, B. T. et al. Population pharmacokinetics and pharmacodynamics of investigational regimens\u2019 drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial. BMJ Open 11, e047185 (2021).","journal-title":"BMJ Open"},{"key":"74335_CR28","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","volume":"387","author":"BT Nyang\u2019wa","year":"2022","unstructured":"Nyang\u2019wa, B. T. et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N. Engl. J. Med. 387, 2331\u20132343 (2022).","journal-title":"N. Engl. J. Med."},{"key":"74335_CR29","doi-asserted-by":"publisher","unstructured":"Rofael, S. et al. M. tuberculosis baseline and acquired drug resistance variants in TB-PRACTECAL clinical trial. Preprint at SSRN https:\/\/doi.org\/10.2139\/ssrn.5941233 (2025).","DOI":"10.2139\/ssrn.5941233"},{"key":"74335_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson, B. J. & Holford, N. H. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharm. Toxicol. 48, 303\u2013332 (2008).","journal-title":"Annu. Rev. Pharm. Toxicol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74335-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74335-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74335-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:21:28Z","timestamp":1785885688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74335-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74335"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74335-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.-T.N., I.M. and C.B. declare employment at M\u00e9decins Sans Fronti\u00e8res (MSF), the sponsor of the TB-PRACTECAL trial, while serving as the Chief Investigator, Medical Monitor and Global Principal Investigator of the TB-PRACTECAL trial, respectively. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7830"}}